成都百事興科技實業(yè)有限公司始建于2003年，公司占地面積18000余平米，位于成都市蒲江縣鶴山鎮(zhèn)工業(yè)北路217號。2011年進(jìn)行了aa期技術(shù)改造工程，新建氨基酸生產(chǎn)線兩條、醫(yī)藥中間體生產(chǎn)線一條，按照**GMP標(biāo)準(zhǔn)建造生產(chǎn)車間5000余平米。通過近9年的升級技術(shù)改造達(dá)到預(yù)期的效果，生產(chǎn)經(jīng)營得到了很大的提升，先后被評為四川省高新技術(shù)企業(yè)、四川省中小企業(yè)協(xié)會理事單位、四川省建設(shè)創(chuàng)新型試點企業(yè)。。公司多個產(chǎn)品被評為成都市“名優(yōu)產(chǎn)品”;擁有多個發(fā)明aa和實用新型aa，部分產(chǎn)品填補了國內(nèi)空白。公司已通過ISO9001：2015質(zhì)量體系**、ISO14001:2015環(huán)境管理體系**、ISO22000:2005食品安全管理體系**、OHSAS18001：2007職業(yè)健康安全管理體系**。公司于2018年通過了安全標(biāo)準(zhǔn)化二級達(dá)標(biāo)。

      成都百事興共有兩個生產(chǎn)基地，占地面積18000余平米，職工人數(shù)近200人，年產(chǎn)量1000噸以上，年銷售額1億元以上。現(xiàn)有4條生產(chǎn)線的成都基地；另一個是位于蘭州占地90畝，即將擁有6條符合cGMP生產(chǎn)線的蘭州基地。主要產(chǎn)品有：乳清酸、DL-高半胱氨酸硫內(nèi)酯鹽酸鹽、雙甘肽、甘氨酰酪氨酸、丙氨酰胱氨酸、甘氨酸叔丁酯鹽酸鹽、D-賴氨酸鹽酸鹽、D-蘇氨酸、L-酪氨酸二鈉、L-焦谷氨酸、乙酰 L-硫代脯氨酸、醫(yī)藥中間體等。產(chǎn)品質(zhì)量按照美國藥典（USP）、歐洲藥典（EP）、日本味之素（AJI）標(biāo)準(zhǔn)生產(chǎn)；廣泛用于醫(yī)藥、食品、化妝品等行業(yè)，公司產(chǎn)品覆蓋全球20多個**和地區(qū)建立了**的**市場網(wǎng)絡(luò)和良好的對外貿(mào)易關(guān)系。

      公司始終以創(chuàng)建外向型、科技型的現(xiàn)代企業(yè)為發(fā)展目標(biāo)，強化自身建設(shè)，扎實做好每項工作，已形成科學(xué)的內(nèi)部管理體系和創(chuàng)新體系；有較強的aa教授、博士、學(xué)者組成的產(chǎn)品研發(fā)團(tuán)隊；具備成熟的生產(chǎn)工藝、**的檢測體系，形成迅速的科技成果轉(zhuǎn)化能力。公司擁有專業(yè)、敬業(yè)的國內(nèi)外市場開拓團(tuán)隊，以求實拼搏、**創(chuàng)新的精神應(yīng)對市場的各種挑戰(zhàn)和變化。公司將以aa的技術(shù)、aa的產(chǎn)品、aa的服務(wù)為人類醫(yī)藥、高端食品行業(yè)做貢獻(xiàn)。

ABOUT US

Headquarter- Chengdu Beishixing Technology Industrial Co., Ltd.

Established in 2003, Chengdu Beishixing Technology Industrial Co., Ltd. is a high-tech enterprise that provides one-stop production of amino acids, protected amino acids, oligopeptides and other related products. For better human health and development, the company is committed to providing first-class products and services.

Chengdu Baishixing has attracted nearly 200 talents of all types, and its core technology and management team have been deeply involved in this industry for more than 20 years. The company is equipped with advanced instruments and equipment.

Chengdu Baishixing has two production bases. One is a Chengdu base located in Chengdu covering an area of 20 acres and currently has 4 production lines; the other is a Lanzhou base located in Lanzhou covering an area of 90 acres and will soon have 6 cGMP-compliant production lines.

Chengdu Baishixing has obtained ISO9001, ISO14001, ISO22000, OHSAS18001 and other series of certifications all year round. Product quality complies with the standards of Chinese Pharmacopoeia(CP), United States Pharmacopoeia(USP), European Pharmacopoeia(EP) and other countries.

As of 2024, Chengdu Baishixing products and services have covered more than 20 countries and regions around the world. We have established long-term cooperation with well-known domestic and foreign pharmaceutical companies including Pfizer, Sanofi, Merck, Qilu Pharmaceuticals, and Asymchem.

In the field of life sciences, Chengdu Baishixing will spare no effort to provide cost-effective products and services.

Gansu Baishixing Pharmaceutical Co., Ltd.

Established in 2020, located in the national-level new area, Lanzhou New District Chemical Industry Park and covering an area of more than 90 acres, Gansu Baishixing Pharmaceutical Co., Ltd. is the wholly subsidiary of Chengdu Baishixing Science and Technology Industrial Co.,Ltd. The company focuses on the development and production of small molecule drug APIs, high-end pharmaceutical intermediates, and new compounds. It is a high-tech enterprise that provides large-scale products and technical services related to APIs and pharmaceutical intermediates to global pharmaceutical companies and scientific research institutions.

公司使命：為人類健康和發(fā)展提供高性價比產(chǎn)品和服務(wù)。

公司愿景：成為世界一流生物智造公司。

公司價值觀：合規(guī)；專注；奮斗；共贏

Company Mission: To  provide affordable high-quality products and services for human health and development.

Company Vision: To be a world-class bio-intelligent manufacturing company.

Company Value: Compliance; Focus;Strive;Win-win

公司歷史

2003成立

2011新工廠啟用

2015石博士團(tuán)隊加入

2021年營收首次破億

2023并購甘肅百事興藥業(yè)

Company History

2003-Setup

2011-New Factory Operated

2015-Dr Shi and his team joined

2021-Initial Annual Turnover of over 100 million CNY

2023-Acquisition of Gansu Baishixing Pharmaceutical Co., Ltd.